[Prevention of supraventricular tachysystole with anti-arrhythmia agents].
The paper substantiates the necessity of using a set of antiarrhythmic drugs for the prevention of supraventricular tachysystoles. In the development of supraventricular tachysystoles an important role is attributed to the disorders in automatic regulation of the sinus node. Cases are described in which the development of paroxysmal cardiac fibrillation with approximately equal intervals of time was caused by an inhibition of the sinus node activity. The set of antiarrhythmic drugs included beta-adrenergic blockers, isocholinic-type drugs, cardiac glycosides, Rauwolfia serpentina preparations, parasympatholitic drugs.
D000328:Adult; D000368:Aged; D000404:Ajmaline / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001463:Barbiturates / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008875:Middle Aged; D010634:Phenobarbital / Q000627:therapeutic use; D013034:Sparteine / Q000627:therapeutic use; D013431:Sulfates / Q000627:therapeutic use; D013614:Tachycardia, Paroxysmal / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; D001463:Barbiturates; D004338:Drug Combinations; D013431:Sulfates; D000404:Ajmaline; D013034:Sparteine; D010634:Phenobarbital
Medikamentoznaia profilaktika supraventrikuliarnykh takhisistoliĭ.